GLENMARK

Glenmark Pharmaceuticals Share Price

₹1,463.50 -29.15 (-1.95%)

21 Nov, 2024 14:40

SIP TrendupStart SIP in GLENMARK

Start SIP

Performance

  • Low
  • ₹1,459
  • High
  • ₹1,494
  • 52 Week Low
  • ₹761
  • 52 Week High
  • ₹1,831
  • Open Price₹1,493
  • Previous Close₹1,493
  • Volume326,994

Investment Returns

  • Over 1 Month -15.82%
  • Over 3 Month -10.65%
  • Over 6 Month + 40.39%
  • Over 1 Year + 86.39%
SIP Lightning

Smart Investing Starts Here Start SIP with Glenmark Pharmaceuticals for Steady Growth!

Invest Now

Glenmark Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • -47.2
  • PEG Ratio
  • 0.1
  • Market Cap Cr
  • 41,298
  • P/B Ratio
  • 5.3
  • Average True Range
  • 63.48
  • EPS
  • 0
  • Dividend Yield
  • 0.2
  • MACD Signal
  • -25.02
  • RSI
  • 29.79
  • MFI
  • 23.03

Glenmark Pharmaceuticals Financials

Glenmark Pharmaceuticals Technicals

EMA & SMA

Current Price
₹1,463.50
-29.15 (-1.95%)
pointer
  • stock-down_img
  • Bullish Moving Average 3
  • stock-up_img
  • Bearish Moving Average 13
  • 20 Day
  • ₹1,626.92
  • 50 Day
  • ₹1,644.16
  • 100 Day
  • ₹1,557.05
  • 200 Day
  • ₹1,365.82

Resistance and Support

1494.57 Pivot Speed
  • R3 1,560.13
  • R2 1,538.92
  • R1 1,515.78
  • S1 1,471.43
  • S2 1,450.22
  • S3 1,427.08

What's your outlook on Glenmark Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Glenmark Pharmaceuticals Ltd. is a global, research-driven pharmaceutical company with a focus on respiratory, dermatology, and oncology. It operates in over 80 countries with 10 manufacturing facilities, providing branded, generics, and specialty products to improve patient outcomes worldwide.

Glenmark Pharms. (Nse) has an operating revenue of Rs. 12,247.64 Cr. on a trailing 12-month basis. An annual revenue de-growth of -5% needs improvement, Pre-tax margin of 0% needs improvement, ROE of -19% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 14% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 67 which is a FAIR score but needs to improve its earnings, a RS Rating of 79 which is FAIR indicating the recent price performance, Buyer Demand at D- which indicates heavy supply, Group Rank of 36 indicates it belongs to a strong industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock definitely has some strength, you may want to examine it in more detail.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Glenmark Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-14 Quarterly Results
2024-08-14 Quarterly Results
2024-05-24 Audited Results & Final Dividend
2024-02-14 Quarterly Results
2023-11-10 Quarterly Results

Glenmark Pharmaceuticals F&O

Glenmark Pharmaceuticals Shareholding Pattern

46.65%
11.41%
0.7%
23.05%
0%
13.6%
4.59%

About Glenmark Pharmaceuticals

  • NSE Symbol
  • GLENMARK
  • BSE Symbol
  • 532296
  • Chairman & Managing Director
  • Mr. Glenn Saldanha
  • ISIN
  • INE935A01035

Similar Stocks to Glenmark Pharmaceuticals

Glenmark Pharmaceuticals FAQs

Glenmark Pharmaceuticals share price is ₹1,463 As on 21 November, 2024 | 14:26

The Market Cap of Glenmark Pharmaceuticals is ₹41298.2 Cr As on 21 November, 2024 | 14:26

The P/E ratio of Glenmark Pharmaceuticals is -47.2 As on 21 November, 2024 | 14:26

The PB ratio of Glenmark Pharmaceuticals is 5.3 As on 21 November, 2024 | 14:26

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23